Loading...

MedXY News - immunotherapy

MedXY AI/MedXY News/Tag: immunotherapy

MedXY News

EnglishTag

immunotherapy

146 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Immune Checkpoint Inhibitors Deliver Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

Immune Checkpoint Inhibitors Deliver Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.

Section: GastroenterologyJun 20, 2026

Checkpoint Blockade Delivers Deep, Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

Checkpoint Blockade Delivers Deep, Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

This single-center cohort found high and durable checkpoint inhibitor responses in dMMR/MSI-H gastroesophageal adenocarcinoma, including complete responses in locoregional disease that may support carefully selected nonoperative management.

Section: GastroenterologyJun 20, 2026

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.

Section: Diabetes & EndocrinologyJun 20, 2026

Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: A Promising First-Line Signal From TROPHAMET

Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: A Promising First-Line Signal From TROPHAMET

TROPHAMET found that first-line avelumab plus methotrexate achieved 96.2% hCG normalization in low-risk gestational trophoblastic tumors with manageable toxicity, no relapses at 41 months, and preserved fertility.

Section: newsJun 20, 2026

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.

Section: Hematology-OncologyJun 7, 2026

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.

Section: newsMay 29, 2026

Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer

Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer

In advanced head and neck squamous cell carcinoma, pretreatment weight loss and low prognostic nutritional index were linked to shorter progression-free survival after immunotherapy, while baseline BMI was not predictive.

Section: newsMay 20, 2026

Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes

Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes

Recent studies demonstrate that combining the beta-cell-targeted conjugate GLP1-E2 with low-dose anti-CD3 therapy significantly delays type 1 diabetes onset by simultaneously reducing immune infiltration and mitigating beta-cell cellular st

Section: Clinical UpdatesMay 20, 2026

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer

A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific com

Section: newsApr 27, 2026

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence ris

Section: GastroenterologyApr 14, 2026

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge

A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.

Section: newsApr 14, 2026

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recu

Section: newsApr 6, 2026

Oncolytic Bovine Herpesvirus Type 1: A Novel Strategy for Immune Microenvironment Remodeling in Multiple Myeloma

Oncolytic Bovine Herpesvirus Type 1: A Novel Strategy for Immune Microenvironment Remodeling in Multiple Myeloma

This review explores the breakthrough potential of Bovine Herpesvirus Type 1 (BoHV-1) as an oncolytic agent in Multiple Myeloma, highlighting its ability to induce mitochondrial apoptosis, reprogram the immunosuppressive bone marrow niche,

Section: Clinical UpdatesApr 6, 2026

Optimizing the Synergy: Sequential vs. Concurrent Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer

Optimizing the Synergy: Sequential vs. Concurrent Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer

This review evaluates the optimal sequencing of radiotherapy and immunotherapy in advanced NSCLC, highlighting real-world evidence from the OCEANUS study favoring sequential over concurrent administration.

Section: Clinical UpdatesApr 3, 2026

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

This review analyzes the 5-year overall survival outcomes of the CAPTAIN-1st trial, establishing camrelizumab plus chemotherapy as a long-term standard of care for recurrent or metastatic nasopharyngeal carcinoma.

Section: Clinical UpdatesMar 20, 2026

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

This review analyzes the Phase 3 Precision-T trial, demonstrating that Orca-T, a high-precision T-cell therapy, significantly improves chronic GVHD-free survival and reduces non-relapse mortality compared to standard-of-care prophylaxis in

Section: Clinical UpdatesMar 21, 2026

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis

This review evaluates how deep learning-assisted delta radiomics on MRI, combined with AFP response, provides a non-invasive, high-accuracy prediction of pathological complete response in unresectable HCC undergoing conversion immunotherapy

Section: Clinical UpdatesMar 16, 2026

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.

Section: Hematology-OncologyMar 13, 2026

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness an

Section: GastroenterologyMar 12, 2026

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

This post-hoc analysis of the HIMALAYA Phase III trial explores the link between immune-mediated adverse events and overall survival in unresectable HCC, revealing that patients on the STRIDE regimen who experienced imAEs had improved survi

Section: GastroenterologyMar 12, 2026

Prev 1 2 3 8 Next